Is acetaminophen, and its combination with pamabrom, an effective therapeutic option in primary dysmenorrhoea?

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 3, 2004, Pages 561-570

  Di Girolamo, Guillermo ^a,c   Sánchez, Adrian J ^b   De Los Santos, Antonio ^a   González, Claudio D ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSIDAD DEL SALVADOR   (Argentina)

^c NONE   (Argentina)

Author keywords

Acetaminophen; COX 3; Cyclooxygenase; Dysmenorrhoea; Menstrual; Pamabrom; Pelvic pain

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIPYRETIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DEXTROPROPOXYPHENE; DIURETIC AGENT; FLURBIPROFEN; IBUPROFEN; INTERFERON; ISONIAZID; LEUKOTRIENE; MEFENAMIC ACID; MIDOL TEEN; NAPROXEN; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PAMABROM; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; PLACEBO; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; RIFAMPICIN; ROFECOXIB; SPASMOLYTIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; WOMEN S TYLENOL MENSTRUAL RELIEF CAPLETS;

ADOLESCENT; ADULT; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHOSPASM; CLINICAL STUDY; CLINICAL TRIAL; DIURETIC ACTIVITY; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDICATION; DRUG INFORMATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; DYSMENORRHEA; FEMALE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMOSTASIS; HUMAN; HYPOTENSION; KIDNEY TUBULE NECROSIS; LIVER FAILURE; LIVER INJURY; LIVER NECROSIS; MENSTRUAL CYCLE; MONOTHERAPY; PAIN ASSESSMENT; PELVIS PAIN SYNDROME; PREVALENCE; PROSTAGLANDIN SYNTHESIS INHIBITION; REPRODUCTION; REVIEW; SCORING SYSTEM; SHOCK; URTICARIA; VOMITING;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; CLINICAL TRIALS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; DYSMENORRHEA; FEMALE; HUMANS; PROPANOLAMINES; THEOPHYLLINE;

EID: 1542610050     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.3.561     Document Type: Review

References (82)

1. COCO AS: Primary dysmenorrhoea. Am. Fam. Physician (1999) 60(2):489-496.
2. PEDRON-NUWVO, GONZALEZ-UNZAGA R, DE CELLIS CARRILLO R et al: Incidence of dysmenorrhoea and associated symptoms in women aged 12-24 years. Ginecol. Obstet. Mex. (1998) 66:492-494.
3. JAMIESON DJ, STEEGE JF: The prevalence of dysmenorrhoea, dyspareunia, pelvic pain, and irritable bowel syndrome in primary care practices. Obstet. Gynecol. (1996) 87:55-58.
4. ANDERSCH B, MILSOM I: An epidemiologic study of young women with dysmenorrhoea. Am. J. Obstet Gynecol. (1982) 144:655-660.
5. DELIGEOROGLOU E: Dysmenorrhoea. Ann. NY Acad Sci. (2000) 900:237-244.
6. SCHROEDER B, SANFILIPPO JS: Dysmenorrhoea and pelvic pain in adolescents. Pediatr. Clin. North Am. (1999) 46(3):555-571.
7. HARLOW SD, PARK M: A longitudinal study of risk factors for the occurrence, duration and severity of menstrual cramps in a cohort of college women. Br. J. Obstet. Gynaecol. (1996) 103:1134-1142.
8. SUNDELL G, MILSOM I, ANDERSCH B: Factors influencing the prevalence and severity of dysmenorrhea in young women. Br. J. Obstet. Gynaecol. (1990) 97:588-594.
9. PARAZZINI F, TOZZI L, MEZZOPANE R, LUCHINI L, MARCHINI M, FEDELE L: Cigarette smoking, alcohol consumption, and risk of primary dysmenorrhoea. Epidemiology (1994) 5:469-472.
10. DAWOOD MY. Current concepts in the etiology and treatment of primary. Acta Obstet. Gynecol. Scand. (1986) 138(Suppl.):7-10.
11. BANIKARIM C, CHACKO MR, KELDER SH: Prevalence and impact of dysmenorrhoea on hispanic female adolescents. Arch. Pediatr. Adolesc. Med. (2000) 154:1226-1229.
12. HILLEN J, GRBAVAC S: Primary dysmenorrhoea in young western Australian woman: Prevalence, impact and knowledge of treatment. J. Adolesc. Health (1999) 25:40-45.
13. KLEIN J, LITT I: Epidemiology of adolescent dysmenorrhoea. Pedriatics (1981) 68:661-664.
14. FORLEO R, SBIROLI C, DI TONDO U: Mestruazione. Fisiopatología della riproduzione femminile (Vol. 9). Gelmini (Ed.), Milano (1982):321-323.
15. HUFFMAN JW, DEWHURST CJ, CAPRARO VJ: The Gynecology of Childhood and Adolescence. WB Saunders, Philadelphia, USA (1981):469-484.
16. PICKLES VR: A plain muscle stimulant in the menstrum. Nature (1957) 180:1198-1199.
17. SMITH RP, POWELL JR: The objective evaluation of dysmenorrhoea therapy. Am. J. Obstet. Gynecol. (1980) 137:314-319.
18. DAWOOD MY: Dysmenorrhoea. Clin. Obstet. Gynecol. (1990) 33(1):168-178.
19. CAMERON IT, CAMPBELL S: Nitric Oxide in the endometrium. Hum Reprod. Update (1998) 4(5):565-569.
20. BIEGLMAYER C, HOFER G, KAINZ C et al.: Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives. Gynecol. Endocrinol. (1995) 9:307-312.
21. NIGAM S, BENEDETTO C, ZONCA M et al.: Increased concentrations of eicosanoids and platelet-activating factor in menstrual blood from women with primary dysmenorrhoea. Eicosanoids (1991) 4:137-141.
22. STOLL SL: Dysmenorrhoea. Secrets in Obstetrics and Ginecol. (Vol. 4). (Ed) Italiana, Intramed Communications, Milan (1992):17-24.
23. DAWOOD MY: Dysmenorrhoea andPprostaglandins: pharmacological and therapeutic considerations. Drugs (1981) 22(1):42-56.
24. REES MCP, ANDERSON ABM, DEMERS LM, TURNBULL A: Endometrial and myometrial prostaglandin released during the menstrual cycle in relation to menstrual blood loss. J. Clin. Endocrinol. Metab. (1984) 58:813.
25. ZONDERVAN KT, YUDKIN PL, VESSEY MP et al.: The prevalence of chronic pelvic pain in women in the UK: A systematic review. Br. J. Obstet. Gynaecol. (1998) 105(1):93-99.
26. DAWOOD MY: Nonsteroidal anti-inflammatory drugs and changing attitudes toward dysmenorrhoea. Am. J. Med. (1988) 84(Suppl. 5A):23-29.
27. DAWOOD MY: Overall approach to the management of dysmenorrhoea. In: Dysmenorrhoea. Dawood MY (Ed.) Williams & Wilkins, Baltimore, USA (1981):261-279.
28. SMITH RP: The use of nonsteroidal anti-inflammatory drugs in primary dysmenorrhoea. Int. Med. J. (1986) 169:22.
29. CARRAHER R, HAHN DW, RITCHIE DM, MCGUIRE JL: Involvement of lipooxygenase products in myometrial contractions. Prostaglandins (1983) 26:23.
30. REES MCP, DIMARZO V, TIPPINS JR, MORRIS HR, TURNBULL AC: Leukotriene release by endometrium and myometrium throughout the menstrual cycle in dysmenorrhoea and menorrhagia. J. Endocrinol. (1987) 113:291.
31. 4 and prostacyclin-binding sites in nonpregnant human uterine tissue. J. Clin. Endocrinol. Metab. (1988) 58:813.
32. STRÖMBERG P, AKERLUND M, FORSLING ML, GRANSTRÖM E, KINDAHL H: Vasopressin and prostaglandins in premenstrual pain and primary dysmenorrhoea. Acta Obstet. Gynecol. Scand. (1984) 63:533.
33. HAUKSSON A, AKERLUND M, MELIN P: Uterine blood flow and myometrial activity at menstruation and the action of vasopressin and a synthetic antagonist. Br. J. Obstet. Gynaecol. (1988) 95:898.
34. STRÖMBERG P, FORSLING M, AKERLUND M: Effect of prostaglandin inhibition of vasopressin levels in women with primary dysmenorrhoea. Obstet. Gynecol. (1981) 58:206.
35. DEMERS LM, HANN DW, MCGUIRE JL: Newer concepts in dysmenorrhoea research. In: Premenstrual Syndrome and Dysmenorrhoea. Dawood MJ, McGuire JL, Demers LM (Eds), Urban & Schwarzenburg, Baltimore, USA (1984):205.
36. MONTRUCCHIO G, MASSOBRIO M, ALLOATTI G et al.: In vitro oxytocic activity of platelet-activating factor on human myometrium. In: Advances in Prostaglandin, Thromboxane and Leukotriene Research. Samuelsson B, Paoletti R, Ramwell PW (Eds), New York, Raven Press (1987).
37. MASSOBRIO M, BENEDETTO C, ROSI A, MAROZIO L, NIGAM S: Eicosanoids and platelet activating factor in dysmenorrhoea. In: Pain and Reproduction. Genazzani AR, Nappi G, Facchinetti F, Martignoni E (Eds), Parthenon Publishing, Carnforth (1988):63.
38. WILLOUGHBY DA, MOORE AR, COLVILLE-NASH PR: COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet (2000) 355:646-668.
39. BOTTING RM: Mechanism of action If acetaminophen: is there a cyclooxygenase 3? Clin. Infect. Dis. (2000) 31(Suppl. 5):S202-S210.
40. CHANDRASEKHARAN NV, DAI H, ROOS KL et al.: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proc. Natl. Acad. Sci. USA (2002) 99:13926-13931.
41. DINCHUK JE, LIU RQ, TRZASKOS JM: Cox-3: in the wrong frame in mind. Immunol. Lett. (2003) 86(1):121.
42. CRAMER DW, HARLOW BL, TITUS-ERNSTOFF L, BOHLKE K, WELCH WR, GREENBERG ER: Over-the-counter analgesics and risk for ovarian cancer. Lancet (1998) 351:104-107.
43. JOBIN RM, NEUMANN CM, CHANG JP: Roles of calcium and calmodulin in the mediation of acute and sustained GnRH-stimulated gonadotropin secretion from dispersed goldfish pituitary cells. Gen. Comp. Endocrinol. (1996) 101:91-106.
44. MUDGE GH: Diuretics. In: The Pharmacological Basis of Therapeutics (5th Edn). Goodman LS, Gilman A (Eds), McGraw and Hill, UK
45. OWEN PR: Prostaglandin synthetase inhibitors in the treatment of primary dysmenorrhoea. Am. J. Obstet. Gynecol. (1984) 148(1):96-103.
46. SMITH RP: Drug therapy for dysmenorrhoea. Int. Med. J. (1986) 169(1):22-25.
47. LAYES MOLLA A, DONALD LF: A comparative study of ibuprofen and acetaminophen in primary dysmenorrhoea. J. Int. Med. Res. (1974) 2(6):395-399.
48. SEDGWICK JP, DAILY HR, LANGRICK AF, HILL RC: Double blind study of meptazinol, d-propoxyphene/acetominophen and placebo in patients with primary dysmenorrhoea. Curr. Ther. Res. (1985) 38:528-535.
49. ANDERSON AB, HAYNES PJ, FRASER IS, TURNBULL AC: Trial of prostaglandin-synthetase in primary dysmenorrhoea. Br. J. Clin. Pract. (1978) 1:345-348.
50. LANGRICK AF, GUNN ADG: A comparison of naproxen sodium and a dextropropoxyphene/acetaminophen combination in the treatment of primary dysmenorrhoea in university health centers. Br. J. Clin. Pract. (1982) 36:181-184.
51. WILLIAMS AA, BLACKHOUSE CI: A general practice study of naproxen sodium and a dextropropoxyphene- acetominophen combination in primary dysmenorrhea. Br. J. Clin. Pract. (1982) 36:383-385.
52. DE LOS SANTOS AR, ZMIJANOVICH R, PEREZ MACRI S, MARTI ML, DI GIROLAMO G: Antispasmodic, analgesic association in primary dysmenorrhoea double/blind crossover placebo/controlled clinical trial. Int. J. Clin. Pharm. Res. (2001) 21(1):21-29.
53. JANBU T, LOKKEN P, NESHEIM BI: Effect of acetylsalicylic acid, acetaminophen and placebo on pain and blood loss in dysmenorrhoeic women. Eur. J. Clin. Pharmacol. (1978) 14(6):413-416.
54. MACLEAN D: A comparison of flurfiprofen and acetaminophen in the treatment of primary dysmenorrhoea. J. Int. Med. Res. (1983) 11(2):1-5.
55. FRANK GJ, KEFFORD RH: Report of a double-blind crossover study to compare flurbiprofen with acetaminophen in the treatment of primary dysmenorrhoea. J. Int. Med. Res. (1983) 11(2):6-10.
56. MILSOM I, ANDERSCH B: Effect of ibuprofen, naproxen sodium and acetaminophen on intrauterine pressure and menstrual pain in dysmenorrhoea. Br. J. Obstet. Gynaecol. (1984) 91(11):1129-1135.
57. PENDERGRASS PB, SCOTT JN, REAM LJ, AGNA MA. Effect of small doses of aspirin and acetaminophen on total menstrual loss and pain of cramps and headache. Gynecol. Obstet. Invest. (1985) 19(1):32-37.
58. ZHANG WY, LI WAN, PO A: Efficacy of minor analgesics in primary dysmenorrhoea: A systematic review. Br. J. Obstet. Gynecol. (1998) 105(7):780-789.
59. MORRISON BW, DANIELS SE, KOTEY P, CANTU N, SEIDENBERG B: Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: A randomized controlled trial. Obstet. Gynecol. (1999) 94(4):504-508.
60. MCADAM BF, CATELLA-LAWSON F, MARDINI IA, KAPOOR S, LAWSON JA, FITZGERALD GA: Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. USA (1999) 96(1):272-277; Erratum in Proc. Natl. Acad. Sci. USA (1999) 96(10):5890.
61. MONCADA S, VANE JR: Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol. Rev. (1978) 30(3):293-331.
62. BRATER DC: Effects of nonsteroidal anti-inflammatory drugs on renal function: Focus on cyclooxygenase-2-selective inhibition. Am. J. Med. (1999) 107(6A):S65-S70.
63. MILSOM I, MINIC M, DAWOOD Y et al.: Comparison of the efficacy and safety of nonprescription dosed of naproxen and naproxen sodium with ibuprofen, acetaminophen, and placebo in the treatment of primary dysmenorrhoea: A pooled analysis of five studies. Clin. Ther. (2002) 24(9):1384-1400.
64. HERSH EV, MOORE PA, ROSS GL: Over-the-counter analgesics and antipyretics: A critical assessment. Clin. Ther. (2000) 22(5):500-548.
65. MYERS WC, OTTO TA, HARRIS E et al.: Acetaminophen overdose as a suicidal gesture: A survey of adolescent's knowledge of its potential toxicity. J. Am. Acad. Child Adolesc. Psychiatry (1992) 31:686-690.
66. KEAYS R, WILLIAMS R: Acetaminophen poisoning and liver failure. Prescr. J. (1989) 29:155-162.
67. MAKIN AJ, WENDON J, WILLIAMS R: Management of severe cases of paracetamol overdosage. Br. J. Hosp. Med. (1994) 52:210-213.
68. JANES J, ROUTLEDGE PA: Recent developments in the management of paracetamol (acetaminophen) poisoning. Drug Saf. (1992) 7:170-177.
69. CRIPPIN JS: AcetaminopheP hepatotoxicity: potentiation by isoniazid. Am. J. Gastroenterol. (1993) 88:590-592.
70. NOLAN CM, SANDBLOM RE, THUMMEL KE, SLATTERY JT, NELSON SD: Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. Chest (1994) 105:408-411.
71. KARAKAYA G, KALYONCU AF: Acetaminophen and asthma. Expert Opin. Pharmacother. (2003) 4(1):13-21.
72. COHEN HA, NUSSINOVITCH M, FRYDMAN M: Fixed drug eruption caused by acetaminophen. Ann. Pharmacother. (1992) 26:1596-1597.
73. HERN S, HARMAN K, CLEMENT M, BLACK MM: Bullous fixed drug eruption due to acetaminophen with an unusual immunofluorescence pattern. Br. J. Dermatol. (1998) 139:1129-1131.
74. VAN DIEM L, GRILLIAT JP: Anaphylactic shock induced by acetaminophen. Eur. J. Clin. Pharmacol. (1990) 38:389-390.
75. NEDOROST SM, TAYLOR JS, CAMISA C, TOMECKI KJ, HELM T. DURKIN VJ: Fixed drug eruption from pamabrom. Cleve. Clin. J. Med. (1991) 58(1):64-65.
76. 2, serum levels in dysmenorrhoeic adolescence before, during and after treatment with oral contraceptives. Eur. J. Obstet. Gynecol. Reprod. Biol. (1990) 36:292-298.
77. GEBHART GF, MCCORMACK KJ: Neuronal plasticity. Implication for pain therapy. Drug (1994) 47(Suppl. 5):1-47.
78. HERNANDEZ BUENO JA, DE LA JARA DIAZ J, SEDENO CRUZ F, LLORENS TORRES F: Analgesic-antispasmodic effect and safety of lysine clonixinate and L-hyoscinbutylbromide in the treatment of dysmenorrhoea. Ginecol. Obstet. Mex. (1998) 66:35-39.
79. KAPLAN B, RABINERSON D, LURIE S et al.: Clinical evaluation of e new model of transcutaneous electrical nerve stimulation device for the management of primary dysmenorrhoea. Gynecol. Obstet. Invest. (1997) 44(4):255-259.
80. TSENOV D: The effect of acupuncture in dysmenorrhoea. Akusk Ginecol. Soffiia (1996) 35(3):24-25.
81. PICCIONE E, NOCCIOU G, CASSADEI L, SESTI F: Attuali aspetti di terapia medica della dismenorrea. Gior. It. Ost. Gyn. (1988) 4:277-281.
82. GRANOT M, YARNITSKY D, ITSKOVITZ-ELDOR J, GRANOVSKY Y, PEER E, ZIMMER EZ: Pain perception in women with dysmenorrhoea. Obstet. Gynecol. (2001) 98(3):407-411.